Anavex Life Sciences Corp (AVXL): THE A2-73 P2B/3 AD TRIAL IS NOT THE OLE...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	16
Posts	5825
Boards Moderated	0
Alias Born	07/16/2018

rayovacAAA

Re: raja48185 post# 364153

Wednesday, 06/22/2022 10:16:39 AM

Wednesday, June 22, 2022 10:16:39 AM

THE A2-73 P2B/3 AD TRIAL IS NOT THE OLE TRIAL!!!!!!!

October 2022 for TLR ? quite possible, but I would not bank on it ; not when the clinical trials site has these dates (see below) and going by the way it has been all along - even though the primary and secondary outcome measures are assessed at 96 weeks (time frame)

https://clinicaltrials.gov/ct2/show/NCT04314934?term=Anavex+Life+Sciences&draw=4&rank=1

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 450 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label Extension Study for Patients With Early Alzheimer's Disease (AD) Enrolled in Study ANAVEX2-73-AD-004

Actual Study Start Date : October 10, 2019
Estimated Primary Completion Date : May 2024
Estimated Study Completion Date : June 2024